セリアック病治療薬市場：薬剤、タイプ、適応症、エンドユーザー別-2025-2030年の世界予測

セリアック病治療薬市場は、2023年に14億2,000万米ドルと評価され、2024年には15億6,000万米ドルに達すると予測され、CAGR 10.59％で成長し、2030年には28億7,000万米ドルに達すると予測されています。

セリアック病治療薬市場調査では、グルテンの摂取により小腸が損傷する自己免疫疾患であるセリアック病の管理と治療の可能性を目的とした医薬品の分析を行う。対象範囲は、症状の緩和、粘膜治癒の促進、免疫調節のための開発中の医薬品のいずれかです。これらの医薬品が必要とされる背景には、セリアック病と診断される患者の増加、グルテンフリーのライフスタイルの認知拡大、厳格なグルテンフリー食以外のアンメットニーズがあります。主な用途には、症状緩和のための医薬品や免疫調節療法が含まれます。最終用途には、病院、研究機関、専門クリニックが含まれます。

市場成長は、ヘルスケア支出の増加、バイオテクノロジーの進歩、患者と医師の意識の高まりに影響されています。しかし、非食餌療法に対する高い需要には大きなビジネスチャンスが潜んでいます。製薬会社は、革新的な製剤や併用療法を活用することができます。研究開発投資を拡大し、規制当局との協力パートナーシップを通じて医薬品承認プロセスを迅速化することで、市場の潜在力を高めることができます。課題としては、厳しい規制のハードル、薬剤開発にかかる高いコスト、新たな治療法の長期的な有効性と安全性を実証する包括的な臨床試験データが限られていることなどが挙げられます。さらに、自己免疫疾患特有の病態生理の複雑さが、薬剤設計に複雑さをもたらしています。

成長のためには、技術革新は個別化医療のアプローチ、治療薬と遺伝的要素の相互作用の探求、経口生物製剤のような代替ドラッグデリバリーシステムによる患者のコンプライアンス強化に焦点を当てるべきです。洞察力に富んだ消費者データ分析によって、研究開発の方向性を特定のサブグループに向けることができ、標準的な治療法を変える可能性があります。市場の競争は激しいが将来性もあり、企業がポートフォリオの多様化とバイオテクノロジーの進歩の活用に努める中で、合併や提携の増加が予想されます。企業は規制動向を積極的に監視し、ゲノムやドラッグデリバリーシステムなどの新技術を統合して医薬品開発パイプラインを加速するための戦略的提携を検討すべきです。進化する市場力学の中で、より広く採用され持続可能なものとなるためには、手頃な価格とアクセスへの対応が引き続き重要です。

市場力学：急速に進化するセリアック病治療薬市場の主要市場インサイトを解明

セリアック病治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • セリアック病の有病率の増加
  • グルテンを含み、すぐに食べられる包装食品への依存度の上昇
  • セリアック病の啓発に向けた政府・民間団体支援の増加
• 市場抑制要因
  • 治療の選択肢の制限
• 市場機会
  • 高度なセリアック病治療薬を導入するための研究開発活動の活発化
  • ヘルスケア分野における技術の進歩と近代化の進展
• 市場の課題
  • 医薬品承認に関する政府の厳しい規制

ポーターの5つの力：セリアック病治療薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：セリアック病治療薬市場における外部からの影響の把握

外部マクロ環境要因は、セリアック病治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析セリアック病治療薬市場における競合情勢の把握

セリアック病治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスセリアック病治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、セリアック病治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨セリアック病治療薬市場における成功への道筋を描く

セリアック病治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • セリアック病の罹患率の増加
    • グルテンを含む加工食品やすぐに食べられる包装食品への依存度が増加
    • セリアック病の啓発に向けた政府および民間団体の支援を増やす
  • 抑制要因
    • 治療選択肢の制限
  • 機会
    • 先進的なセリアック病治療薬を導入するためのR&D活動の活発化
    • ヘルスケア分野における技術の進歩と近代化の進展
  • 課題
    • 医薬品の承認に関する政府の厳しい規制
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 セリアック病治療薬市場薬物別

• 第一選択治療
• 第二選択治療

第7章 セリアック病治療薬市場：タイプ別

• ステロイドと免疫抑制剤
• 治療ワクチン
• ビタミンと栄養補助食品

第8章 セリアック病治療薬市場適応症別

• 拒食症
• 膨満感
• 下痢
• 膨張
• 倦怠感
• ガス

第9章 セリアック病治療薬市場：エンドユーザー別

• 臨床調査機関
• 病院・クリニック
• 調査・学術機関

第10章 南北アメリカのセリアック病治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域のセリアック病治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカのセリアック病治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• Adaptive Biotechnologies Corp.
• Almirall SA
• Amgen Inc.
• Amneal Pharmaceuticals LLC
• AMYRA Biotech AG
• Artielle Immunotherapeutics Inc.
• BioLineRx Ltd.
• Bristol Myers Squibb Company
• Calypso Biotech SA
• GlaxoSmithKline PLC
• Glenmark Pharmaceuticals Ltd.
• Inovera Bioscience
• Johnson & Johnson Services, Inc
• Pfizer Inc.
• Precigen Inc.
• Sanofi S.A.
• Takeda Pharmaceutical Co. Ltd.
• Vactech Oy
• Zedira GmbH

LIST OF FIGURES

• FIGURE 1. CELIAC DISEASE DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. CELIAC DISEASE DRUGS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. CELIAC DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. CELIAC DISEASE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CELIAC DISEASE DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CELIAC DISEASE DRUGS MARKET DYNAMICS
• TABLE 7. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY FIRST LINE OF TREATMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SECOND LINE OF TREATMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY STEROIDS & IMMUNOSUPPRESSIVE DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPEUTIC VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY VITAMINS & DIETARY SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ANOREXIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY BLOATING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DIARRHEA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DISTENSION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY FATIGUE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY GAS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY CLINICAL RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 36. BRAZIL CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 37. BRAZIL CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 38. CANADA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 39. CANADA CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 40. CANADA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 41. CANADA CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 43. MEXICO CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 44. MEXICO CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 45. MEXICO CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 48. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 49. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 50. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 53. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 54. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 55. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 56. AUSTRALIA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 57. AUSTRALIA CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 58. AUSTRALIA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 59. AUSTRALIA CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 60. CHINA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 61. CHINA CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 62. CHINA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 63. CHINA CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 64. INDIA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 65. INDIA CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 66. INDIA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 67. INDIA CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 68. INDONESIA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 69. INDONESIA CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 70. INDONESIA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 71. INDONESIA CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 72. JAPAN CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 73. JAPAN CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 74. JAPAN CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 75. JAPAN CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 76. MALAYSIA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 77. MALAYSIA CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 78. MALAYSIA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 79. MALAYSIA CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 80. PHILIPPINES CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 81. PHILIPPINES CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 82. PHILIPPINES CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 83. PHILIPPINES CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 84. SINGAPORE CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 85. SINGAPORE CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 86. SINGAPORE CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 87. SINGAPORE CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH KOREA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH KOREA CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 90. SOUTH KOREA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 91. SOUTH KOREA CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 92. TAIWAN CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 93. TAIWAN CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 94. TAIWAN CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 95. TAIWAN CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 96. THAILAND CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 97. THAILAND CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 98. THAILAND CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 99. THAILAND CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 100. VIETNAM CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 101. VIETNAM CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 102. VIETNAM CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 103. VIETNAM CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 106. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 107. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 108. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 109. DENMARK CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 110. DENMARK CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 111. DENMARK CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 112. DENMARK CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 113. EGYPT CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 114. EGYPT CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 115. EGYPT CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 116. EGYPT CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 117. FINLAND CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 118. FINLAND CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 119. FINLAND CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 120. FINLAND CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 121. FRANCE CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 122. FRANCE CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 123. FRANCE CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 124. FRANCE CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 125. GERMANY CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 126. GERMANY CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 127. GERMANY CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 128. GERMANY CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 129. ISRAEL CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 130. ISRAEL CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 131. ISRAEL CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 132. ISRAEL CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 133. ITALY CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 134. ITALY CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 135. ITALY CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 136. ITALY CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 137. NETHERLANDS CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 138. NETHERLANDS CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 139. NETHERLANDS CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 140. NETHERLANDS CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 141. NIGERIA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 142. NIGERIA CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 143. NIGERIA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 144. NIGERIA CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 145. NORWAY CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 146. NORWAY CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 147. NORWAY CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 148. NORWAY CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 149. POLAND CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 150. POLAND CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 151. POLAND CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 152. POLAND CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 153. QATAR CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 154. QATAR CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 155. QATAR CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 156. QATAR CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 157. RUSSIA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 158. RUSSIA CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 159. RUSSIA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 160. RUSSIA CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 161. SAUDI ARABIA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 162. SAUDI ARABIA CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 163. SAUDI ARABIA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 164. SAUDI ARABIA CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 166. SOUTH AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 167. SOUTH AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 168. SOUTH AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 169. SPAIN CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 170. SPAIN CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 171. SPAIN CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 172. SPAIN CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 173. SWEDEN CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 174. SWEDEN CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 175. SWEDEN CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 176. SWEDEN CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 177. SWITZERLAND CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 178. SWITZERLAND CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 179. SWITZERLAND CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 180. SWITZERLAND CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 181. TURKEY CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 182. TURKEY CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 183. TURKEY CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 184. TURKEY CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 185. UNITED ARAB EMIRATES CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 186. UNITED ARAB EMIRATES CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 187. UNITED ARAB EMIRATES CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 188. UNITED ARAB EMIRATES CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 189. UNITED KINGDOM CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 190. UNITED KINGDOM CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 191. UNITED KINGDOM CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 192. UNITED KINGDOM CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 193. CELIAC DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 194. CELIAC DISEASE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

The Celiac Disease Drugs Market was valued at USD 1.42 billion in 2023, expected to reach USD 1.56 billion in 2024, and is projected to grow at a CAGR of 10.59%, to USD 2.87 billion by 2030.

Celiac Disease Drugs market research involves analyzing pharmaceuticals aimed at managing and potentially treating Celiac disease, an autoimmune disorder where gluten ingestion damages the small intestine. The scope covers drugs that either alleviate symptoms, promote mucosal healing, or are in development for immune modulation. The necessity for these drugs is driven by the increasing prevalence of diagnosed Celiac cases, expanding gluten-free lifestyle awareness, and the unmet need beyond a strict gluten-free diet. Key applications include pharmaceuticals for symptomatic relief and immune modulation therapies. End-use scopes involve hospitals, research institutions, and specialty clinics.

Market growth is influenced by rising healthcare expenditures, advancements in biotechnology, and heightened patient and physician awareness. However, substantial opportunities lie in the high demand for non-dietary therapeutics. Pharmaceutical companies can capitalize on innovative drug formulations and combination therapies. Expanding R&D investments and expediting drug approval processes through collaborative partnerships with regulatory authorities could enhance market potential. Challenges include stringent regulatory hurdles, high costs of drug development, and limited comprehensive clinical trial data demonstrating long-term efficacy and safety of emerging treatments. Additionally, the inherent complexity of autoimmune pathophysiology poses complications in drug design.

For growth, innovation should focus on personalized medicine approaches, exploring genetic component interactions with therapeutics, and enhancing patient compliance through alternative drug delivery systems such as oral biologics. Insightful consumer data analytics could redirect R&D towards specific subgroups, potentially changing standard care practices. The market's nature is competitive yet promising, with increased mergers and partnerships anticipated as firms strive to diversify portfolios and leverage biotechnological advancements. Businesses should actively monitor regulatory trends and consider strategic alliances to integrate emerging technologies like genomics and drug delivery systems to accelerate drug development pipelines. Addressing affordability and access remains crucial for wider adoption and sustainability in evolving market dynamics.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Celiac Disease Drugs Market

The Celiac Disease Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growth in prevalence of celiac disease
  • Rising dependence of gluten containing and ready-to-eat packaged food
  • Increase government and private organizations support towards celiac disease awareness
• Market Restraints
  • Restricted availability of treatment options
• Market Opportunities
  • Rising R&D activities to introduce advanced celiac disease drugs
  • Technological advancements and increasing modernization in the healthcare sector
• Market Challenges
  • Strict government regulations for drug approval

Porter's Five Forces: A Strategic Tool for Navigating the Celiac Disease Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Celiac Disease Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Celiac Disease Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Celiac Disease Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Celiac Disease Drugs Market

A detailed market share analysis in the Celiac Disease Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Celiac Disease Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Celiac Disease Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Celiac Disease Drugs Market

A strategic analysis of the Celiac Disease Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Celiac Disease Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adaptive Biotechnologies Corp., Almirall SA, Amgen Inc., Amneal Pharmaceuticals LLC, AMYRA Biotech AG, Artielle Immunotherapeutics Inc., BioLineRx Ltd., Bristol Myers Squibb Company, Calypso Biotech SA, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Ltd., Inovera Bioscience, Johnson & Johnson Services, Inc, Pfizer Inc., Precigen Inc., Sanofi S.A., Takeda Pharmaceutical Co. Ltd., Vactech Oy, and Zedira GmbH.

Market Segmentation & Coverage

This research report categorizes the Celiac Disease Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug, market is studied across First Line of Treatment and Second Line of Treatment.
• Based on Type, market is studied across Steroids & Immunosuppressive Drugs, Therapeutic Vaccines, and Vitamins & Dietary Supplements.
• Based on Indication, market is studied across Anorexia, Bloating, Diarrhea, Distension, Fatigue, and Gas.
• Based on End-User, market is studied across Clinical Research Organizations, Hospitals & Clinics, and Research & Academic Institutes.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growth in prevalence of celiac disease
    • 5.1.1.2. Rising dependence of gluten containing and ready-to-eat packaged food
    • 5.1.1.3. Increase government and private organizations support towards celiac disease awareness
  • 5.1.2. Restraints
    • 5.1.2.1. Restricted availability of treatment options
  • 5.1.3. Opportunities
    • 5.1.3.1. Rising R&D activities to introduce advanced celiac disease drugs
    • 5.1.3.2. Technological advancements and increasing modernization in the healthcare sector
  • 5.1.4. Challenges
    • 5.1.4.1. Strict government regulations for drug approval
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Celiac Disease Drugs Market, by Drug

• 6.1. Introduction
• 6.2. First Line of Treatment
• 6.3. Second Line of Treatment

7. Celiac Disease Drugs Market, by Type

• 7.1. Introduction
• 7.2. Steroids & Immunosuppressive Drugs
• 7.3. Therapeutic Vaccines
• 7.4. Vitamins & Dietary Supplements

8. Celiac Disease Drugs Market, by Indication

• 8.1. Introduction
• 8.2. Anorexia
• 8.3. Bloating
• 8.4. Diarrhea
• 8.5. Distension
• 8.6. Fatigue
• 8.7. Gas

9. Celiac Disease Drugs Market, by End-User

• 9.1. Introduction
• 9.2. Clinical Research Organizations
• 9.3. Hospitals & Clinics
• 9.4. Research & Academic Institutes

10. Americas Celiac Disease Drugs Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Celiac Disease Drugs Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Celiac Disease Drugs Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Adaptive Biotechnologies Corp.
• 3. Almirall SA
• 4. Amgen Inc.
• 5. Amneal Pharmaceuticals LLC
• 6. AMYRA Biotech AG
• 7. Artielle Immunotherapeutics Inc.
• 8. BioLineRx Ltd.
• 9. Bristol Myers Squibb Company
• 10. Calypso Biotech SA
• 11. GlaxoSmithKline PLC
• 12. Glenmark Pharmaceuticals Ltd.
• 13. Inovera Bioscience
• 14. Johnson & Johnson Services, Inc
• 15. Pfizer Inc.
• 16. Precigen Inc.
• 17. Sanofi S.A.
• 18. Takeda Pharmaceutical Co. Ltd.
• 19. Vactech Oy
• 20. Zedira GmbH